September 2015 1 Exhibit 99.1

2

What’s New? • Completed Acquisition of Bio-Reference Laboratories August 20, 2015 • Acquired EirGen Pharma, a Growing, Profitable Specialty Pharmaceutical Developer and Manufacturer • Rayaldee™ PDUFA Date – March 29, 2016 • 4Kscore® Included in NCCN Guidelines - CPT Code Became Active on July 1, 2015 – Company Began Billing Insurance for the Test • Enrolling Patients for Long-Acting Factor VIIa-CTP Phase IIa Clinical Trial to Commence Q4 3

A High-Growth Diversified Medical Products Company - Innovative technologies: Antibodies Anti-virals Cardiovascular devices RNAi 4 Diagnostics - Bio Reference Laboratories – a unique clinical lab - 4Kscore® blood test for aggressive prostate cancer risk - Claros 1® immunoassay system for rapid, lab quality in-office testing Pharmaceuticals - Vitamin D therapeutics for SHPT - Platform technology to make peptides and proteins long- acting for treatment of growth hormone deficiency, hemophilia, obesity, etc. - Calcium-free, magnesium-based phosphate binder Opportunistic Investments - Established businesses in: United States Chile Spain Uruguay Israel Mexico International Markets Ireland

Acquired EirGen Pharma, Ltd. • Developer of High Potency Specialty Pharmaceutical Products – Growing, profitable and cash flow positive – Cancer chemotherapy and other niche, high potency drugs require special expertise and infrastructure - significant barriers to entry • Rich Pipeline of Products – 10 product applications filed with the FDA, 3 approved, 4 filings in Europe, all approved, and 5 in Japan, 4 approved – Over 27 additional drugs in development – Opportunities to commercialize products through OPKO operations world-wide • Product registrations by OPKO Chile with others expected • State-of-the-Art High Containment R&D and Manufacturing Facility – Approved by the FDA, EMEA (European Health Authorities) and PMDA (Japan) – Potential to manufacture OPKO’s current and future products with resulting higher gross margins • Co-Founded by Former IVAX Pharmaceuticals Executives 5

Bio-Reference is a Unique Clinical Lab Asset – Acquisition closed August 20, 2015 6 Demonstrated strong, consistent organic growth - 21 years of ~20% compound annual revenue growth Created and expanded franchises in multiple specialty markets including oncology, women’s health and genetics in lab testing and healthcare provider communities Commercialized innovations in clinical testing and informatics: GenPap, PanEthnic Carrier Screen, OnkoSight, Genome DX, Next-Gen Clinical Testing, Whole Exome Sequencing, PsiMedica and CareEvolve Positioned itself securely on the cutting edge of Genetic Medicine through GeneDx Built a strong corporate culture with an outstanding industry leading medical and scientific team with long company tenure and strong commitment to BRLI 1 2 3 4 5

Transaction Rationale: Near-term Extensive phlebotomy draw stations offer synergistic opportunity for efficient commercialization of 4Kscore test for high-grade prostate cancer ~175 BRLI patient service centers located throughout the US for collection of patient specimens Leverage the national marketing, sales, and distribution resources of BRLI to enhance sales of OPKO’s diagnostic platforms ~420 sales and marketing personnel ~5,000 people working together to support the needs of clients and patients Near-term profitability supports the development of existing pharmaceutical pipeline 7 Leverage BRLI’s channels to accelerate the adoption of OPKO’s diagnostic products 1

Transaction Rationale: Longer-term 8 Utilization of genomic data for personalized therapy 2 BRLI’s vast array of genetics and genomics data should benefit OPKO in its drug discovery and clinical trial programs GeneDx was the first commercial laboratory to offer next generation sequencing for panels Offers 620+ single gene tests along with numerous panel-based tests, including inherited cancers, to over 250 providers in 25 countries, many unique to GeneDx Performs more whole exome testing than any other commercial laboratory in the world OPKO’s research capabilities deepen the insights into the genetic information and further strengthen the GeneDx offering

Shared Resources: infrastructure and senior management, scientific expertise and clinical acumen Unique Specialty Capabilities: market (product) specific expertise, specialized clinical connection and applications and focused product managers and marketing materials Each Specialty Sales unit shares some resources but distinctly identifies itself by specialty Target Markets: • Hematologists • Oncologists • Hospital Pathologists Key Services: • Bone Marrow Morphology • Flow Cytometry • Cancer Genetics • MicroArray, FISH • NextGen Seq for Bloods and Solid tumors • Special Coagulation Studies Oncology Routine Clinical Testing Target Markets: • Physician Offices • Health Facilities • FQHCs Key Services: • Automated, High Volume, Routine Testing • HIV, HepC and Other Molecular Tests • GCI Informatics • Heart Health • Regulatory Reporting Women’s Health Target Markets: • Obstetricians • Gynecologists Key Services: • Image Directed Paps • HPV Genotyping • GenPap STI Testing • NonInvasive PreNatal • Reproductive Genetics • Prenatal Cytogenetics • Special Coagulation Studies Genetics Target Markets: •Geneticists •Medical Centers •Children’s Hospitals •Clinicians with Specialties Affected by Genetics Key Services: •DNA Sequencing •aCGH Array Testing •NextGen Sequencing Laboratorio Buena Salud Target Markets: • Medical Clinics • Diabetes Programs • Latino Physicians Key Services: • Automated, High Volume, Routine Testing • GCI Informatics • HIV, HepC and Other Molecular Tests • Formularies • Regulatory Reporting Bio-Reference has Developed Capability in Specialty Areas

The 4Kscore Test as a Minimally Invasive Alternative to Prostate Biopsy Clinical utility is based on three decades of clinical biomarker research and over 20,000 men tested in Europe and the US Identifies the actual risk of aggressive prostate cancer for the individual patient with: High grade prostate cancer pathology Poor prostate cancer clinical outcomes within 20 years Has high sensitivity and high negative predictive value for aggressive prostate cancer 40–56% cost savings to potentially avoid unnecessary MRI and prostate biopsies The only blood test that accurately identifies risk for aggressive prostate cancer 10 1 million U.S. biopsy patients per year; over 2 million patients world-wide

What is the 4Kscore Test? 11 + Age, DRE, and prior biopsy status % risk of having aggressive prostate cancer for an individual patient Components Components OPKO { 4 kallikrein levels: Total PSA Free PSA Intact PSA hK2 Results Results OPKO ALGORITHM

Monitor w PSA or PCA3, ConfirmMDx OncotypeDx or Prolaris 100,000 Standard TRUS or mp MRI-Guided Biopsy Negative Biopsy Histopathology 55,000 25,000 Gleason score 6 Histopathology Biopsy Result Primary Treatment Surgery / Radiation Gleason score 7 Histopathology 20,000 140,000 Abnormal PSA or DRE 700,000 PSA Screenings 12,000 with Confirmed Indolent Disease Active Surveillance 7,500 Primary Treatment Surgery / Radiation 17,500 12 4,000 Serious Infections

Monitor w PSA if abnormal, 4Kscore Biopsy Result Primary Treatment Surgery / Radiation Active Surveillance Primary Treatment Surgery / Radiation Negative Biopsy Histopathology Gleason score 7 Histopathology Gleason score 6 Histopathology OncotypeDx or Prolaris Standard TRUS or mp MRI-Guided Biopsy 36% Biopsy Reduction $78M Savings 29% Reduction$16 M Savings 29% Reduction$146 M Savings $143 M net savings / $1,400 per patient 100,000 Prostate Biopsy Patients 700,000 PSA Screenings 13 51% Reduction$22 M Savings

The 4Kscore Test Predicts Metastases Within 20 years¹ 16% <  2% 4Kscore Test 7.5% 4Kscore Test 7.5% ¹ Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case–Control Study European Urology (in press) 14

4Kscore Commercial Update • 4Kscore ProtecT study published – over 6,000 subjects – Total now 22,000 subjects studied with 4K panel • Over 1,000 US urologists have used the 4Kscore test in routine practice • American Urological Society Meeting in New Orleans May, 2015 – six podium or poster presentations • NCCN Early Detection Guidelines Published July 2015 • Next milestone: – Medicare and private insurance coverage for test: 2015/16 15

Claros ® 1: Rapid Testing in the Physician Office 1-2 mins 10 mins 16 Quantitative Results Insert cassette into Claros®1 analyzer Snap cartridge into Sangia™ cassette Finger stick blood sample

Claros 1 Platform Addresses Large Testing Markets • PSA – US test volume: 30 million tests, $750 M – Intended use to focus on detection claim – Modular PMA filing with FDA in 2016 • Other Test Menus in Development – Aligned with BRL specialty sales focus • Sectors – Oncology – Women’s Health – Health and Wellness 17

OPKO Pharmaceuticals–Advanced, Deep Pipeline 18 Product Indication Preclinical Phase 1 Phase 2 Phase 3 Milestone Market Size Rayaldee™ (CTAP101) SHPT (CKD Stage 3-4 Patients) PDUFA date March 29, 2016 $12.0 BN hGH-CTP hGH deficiency $3.0 BN Alpharen™ (Fermagate) Hyperphosphatemia (CKD Stage 5 Patients) $1.2 BN Rolapitant CINV PDUFA date September 5, 2015 $1.5 BN CTAP201 Mild to moderate SHPT (CKD Stage 5 Patients) $1.1 BN Factor VIIa- CTP Hemophilia Phase 2a trial expected in 4Q 2015 $1.7 BN Oxyntomodulin Diabetes, Obesity Phase I trial targeted for Q1 2016 $15 BN AntagoNAT Platform Cancer, CV, metabolic and orphan disease $1.0 BN CYP24 Inhibitors SHPT, CKD, cancer $1.0 BN Collaboration with Pfizer Outlicensed to TESARO

Rayaldee – A Late-Stage Investigational Drug • Modified-release (MR) oral formulation of 25D 3 * addresses significant unmet market need • Safe and effective treatment for elevated PTH (SHPT) associated with low 25D levels in Stages 3–4 CKD • Achieves more reliable increases in serum 25D and reductions in plasma PTH than nutritional vitamin D • Lower risk of side effects compared to active 1,25D ** products • Preserves protective renal feedback mechanism, reducing upregulation of CYP24 which limits effectiveness of current hormone replacement therapies • Additional potential for new indications including stage 5 CKD, institutionalized elderly, osteoporosis & cancer 19 Product Overview Product Overview * 25-Hydroxyvitamin D3 or Calcifediol ** 1,25-Dihydroxyvitamin D3 or Calcitriol

Market Opportunity: Chronic Kidney Disease (US) • The CKD patient population is large and growing as a result of: – Obesity – Hypertension – Diabetes 20 *US Renal Data Service 2013 Annual Data Report Sources: Levin, A et al., Kidney International 2007; 71: pp.31-38; Gonzalez, E et al. Am J Nephrol 2004;24:503-510; LaClair, R et al. Am J Kidney Dis 2005;45:1026-1033; Tentori, F et al., Clin J Am Soc Nephrol 2015; 10:98-109 % of CKD Patients with Stage Kidney Function CKD Prevalence Vitamin D Insufficiency ( 25D) SHPT ( PTH) Hyperphosphatemia ( Phosphorus) 3 Moderate impairment 18.7 Million* 71% 40% 37% 4 Severe impairment 1.4 Million* 83% 82% 50% 5 Failure 0.5 Million* 97% 95% 70%

Comparison of Vitamin D Therapies for Stage 3-4 CKD Effect on Blood Levels of: Drug Active Type 25D ** Ca iPTH Rayaldee Calcifediol (25-hydroxyvitamin D3) Rx Vitamin D Cholecalciferol/Ergocalciferol (vitamin D3/vitamin D2) OTC Drisdol ™* Ergocalciferol (vitamin D2) Rx Rocaltrol ™* Calcitriol (1a,25-dihydroxyvitamin D3) Rx Hectorol ™* Doxercalciferol (1a-hydroxyvitamin D2) Rx Zemplar ™* Paricalcitol (19-nor-1a,25-dihydroxyvitamin D2) Rx *And generics **25-hydroxyvitamin D 21

Rayaldee - Commercial Opportunity Source: BioTrends Research Group, Inc. December 2013 Untreated 26-44% Vitamin D Hormone 14-25% Nutritional Vitamin D 39-44% Untreated 31-47% Safety concerns; exacerbates vitamin D insufficiency Efficacy Concerns Stage 3 & 4 CKD Treatment for SHPT Rayaldee is expected to take significant market share in Stage 3 and 4 CKD patients suffering from SHPT – a potential $12 billion revenue opportunity 22

Rayaldee Top-Line Phase 3 Data: Plasma iPTH 23

Rayaldee Top-Line Phase 3 Data: Serum 25D 24

Rayaldee Top-Line Phase 3 Data: Serum Ca & P 25 * Significantly different from placebo, p < 0.05 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Time (Weeks) Placebo Placebo to Modified-Release Calcifediol Modified-Release Calcifediol Modified-Release Calcifediol Continuation Placebo-Controlled Extension Serum Calcium Serum Phosphorus * * * * * * *

Rayaldee – Steps to Commercialization • NDA  filing (accepted for full FDA review) in late July • Marketing & sales management team to be hired in Q3-Q4 2015 • PDUFA date:  March 29, 2016 • Launch expected within 3 months of PDUFA date • Initial line extension plans: – Additional phase 3 clinical trial(s) planned in stage 5 CKD – Initial clinical trial ongoing for new oncology indication – Other indications being evaluated 26

OPKO Biologics: Extends the Half-Life of Protein Drugs • Significant reduction in injection frequency • Safety profile comparable to non-modified active therapeutic agents • Potential expanded prophylactic uses with longer half life agents, in addition to short-term treatment • Maintain drug bio-activity 27 Reversible Pegylation Technology CTP Technology Developing biobetter long acting proteins and peptides

CTP Increases Protein Circulation Time 28 + = Any Short-Lasting Protein CTP Long-Lasting Protein CTP – A Natural Chemical Entity Created During Evolution to Enhance Longevity of the Hormone hCG

Global Collaboration with Pfizer for OPKO’s Long- Acting Human Growth  Hormone (hGH-CTP) 29 Collaboration Terms: – $295 M up-front payment – $275 M for achievement of regulatory based milestones – OPKO responsible for funding development program for the key indications: • Adult and Pediatric Growth Hormone Deficiency (GHD) • Pediatric Short for Gestational Age – Pfizer responsible for funding: • Development programs for additional indications • All Post Marketing Studies • All Commercialization Activities – Initial double digit tiered royalties on sales of Adult GHD – Profit sharing commencing upon launch for Pediatric GHD encompassing combined sales for all indications of OPKO’s hGH-CTP and Pfizer’s Genotropin – Pfizer Genotropin represents about 25% of the world market with annual revenues exceeding $700 M Financial Commercial Development

hGH-CTP Competitive Advantages • New molecular entity and maintain natural native sequence of GH • Human growth hormone is used for: – Growth hormone deficient children – Growth hormone deficient adults – SGA, PWS, ISS • Once-a-week injection (current products require daily injections) • Final Presentation: – The drug product will be a refrigerated, liquid non viscous formulation – Injected using a disposable easy to handle pen device with a thin needle and low injection volume • Pivotal Phase 3 study in growth hormone deficient adults (on-going) • Phase 2 study in naive growth hormone deficiency pediatric population has been completed • Orphan drug designation in the US & EU for the treatment of children & adults with GHD 30

Daily hGH Market is $3B, Undifferentiated and Growing 31 Established and growing Established and growing Fragmented Fragmented Daily 2013 Daily 2018 Long-acting potential market Projected market growth Projected market growth Competition based on history, service and device innovation Competition based on history, service and device innovation $3B+ ~$4B Pediatric GHD Pediatric GHD ($1.5B) Adult GHD ISS, Turner Syndrome Other 80% Source: Market Research 2013 & 2014 Novo Nordisk (Norditropin) 31% Pfizer (Genotropin) 23% Eli Lilly (Humatrope) 12% Sandoz (Omnitrope) 8% Merck KGaA (Saizen, Serostim) 8% Roche (Nutropin) 12% Others 6%

MOD-5014: Long-acting Factor VIIa for Hemophilia A & B • $1.7 billion market – Growing 7% annually – Only 25% of patients are treated • Current product (NovoSeven®) requires frequent  IV  doses – 3-4  times a day during bleeding episodes  – 1-2  times a day for prophylactic treatment • Pharmacological studies in hemophilic mice and dogs FVIIa-CTP  demonstrated: – Potential for via subcutaneous administration – Reduced frequency of injection during on-demand therapy – Enable prophylactic treatment while reducing the frequency of injections to 2-3 times a week • Phase 2a study to Commence Q4 • Orphan drug designation in the US and EU 32

Oxyntomodulin – Nature’s Appetite Control Mechanism • Natural appetite suppressor • Oxyntomodulin is a dual GLP-1/Glucagon receptor agonist • Secreted by the digestive system following food intake and induces satiety in the brain • Crosses blood-brain barrier to induce satiety • Increases glucose tolerance in insulin resistance pre-diabetic state associated with obesity 33 Development challenge:  Oxyntomodulin has short half-life which requires multiple daily injections OPKO solution:  MOD-6030, a reversible PEG 30 formulation which provides 12-fold reduction in dosing frequency

MOD 6031: Meets Unmet Market Need • MOD-6031 significantly inhibits food intake and reduces body weight by reduction in fat • MOD-6031 improves glycemic control by inducing glucose dependent insulin secretion (direct mechanism) and by reducing fat (indirect mechanism) • MOD-6031 improves lipid profile • MOD-6031 is expected to provide effective long-term therapy for obese and type II diabetes patients • A battery of comprehensive toxicological studies have been completed confirming the safety of MOD-6031 following a single  injection • Phase 1 study evaluating the safety and pk-pd profile of  MOD-6031 in overweight or obese health volunteers is scheduled to be initiated in early Q1 2016 34

Rolapitant – Potential Near-Term Revenue Driver • Rolapitant out-licensed to Tesaro in December 2010 – Payments of up to $121 million – Double-digit tiered royalties • Differentiated cancer supportive care product with $1.5B US Market Opportunity – Potent neurokinin-1(NK-1) receptor antagonist for chemotherapy-induced nausea and vomiting (CINV) – Opportunity to differentiate on convenience, market access and safety • Single dose • Lack of CYP 3A4 drug-drug interactions • Long acting • Oral and IV formulations allow full market access • PDUFA Date September 5, 2015 – All three Phase 3 trials (MEC* and HEC**) achieved primary endpoint – Primary endpoint: complete response (no emesis and no use of rescue medication) – Third Phase 3 trial (HEC) also achieved all secondary endpoints, including: • Complete response in acute (0-24 hrs) and overall (0-120 hrs) phase of CINV • No significant nausea – Successful completion of bioequivalence study for intravenous formulation 35 ¹ Moderately emetogenic chemotherapy ² Highly emetogenic chemotherapy

Strategic Investments • ARNO Therapeutics, Inc. (OTC: ARNI) (~4% equity interest) – Anti-progestin therapy for breast (phase 2) , endometrial and prostate cancers • Zebra Biologics, Inc. (~27% equity interest) – Combinatorial antibody libraries based on function in human cell screens • OAO Pharmsynthez (MICE: LIFE) (~17% equity interest) – Russian developer and marketer of new drugs • RXi Pharmaceuticals Corporation (NASDAQ: RXII) (~10% equity interest) – sRNA to prevent hypertrophic scars  (phase 2) • Cocrystal Pharma, Inc. (OTC: COCP) (~8% equity interest) – New anti-virals (Hepatitis C, flu) superior molecules for combination therapy (pan-genotypic) • Sevion Therapeutics, Inc. (OTC:  SVON) (~ 4% equity interest*) – Antibodies against difficult targets (e.g., G protein-coupled receptor, ion channels) • Neovasc, Inc. (NASDAQ: NVCN) (~ 5% equity interest) – Cardiology devices (transcutaneous mitral valve) • ChromaDex, Inc. (OTC: CDXC) (~ 2% equity interest) – New nutritional supplement APIs • MabVax Therapeutics Holdings, Inc. (OTC: MBVX) (~7% equity interest) – Cancer Immunotherapy Company • SciVac Therapeutics, Inc (TSX: VAC) (~25% equity interest) – Third-generation hepatitis B vaccine As of June 30, 2015 Proprietary Technologies with Significant Upside Potential 36